Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mitsuo Higashimori

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Journal of Pharmacokinetics and Pharmacodynamics|December 3, 2003
Mean hepatic recovery ratio in capacity-limited first-pass effect by three-point sampling methodMitsuo Higashimori, Kiyoshi Yamaoka
Journal of Pharmaceutical Sciences|April 3, 2020
Physiologically Based Pharmacokinetic Modelling of Glycopyrronium in Patients With Renal ImpairmentMitsuo Higashimori, Kensuke Ishikawa, Michael Gillen, et al.
International Journal of Clinical Pharmacology and Therapeutics|October 29, 2019
Physiologically based pharmacokinetic modeling to predict exposures in healthy Japanese subjects with different CYP2C19 phenotypes: Esomeprazole case study
Mitsuo Higashimori, Hitoshi Shimada, Katsuomi Ichikawa, et al.
Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica|January 3, 2023
[Andexanet alfa (ONDEXXYA<sup>®</sup> for Intravenous Injection 200 mg), a reversal agent for direct factor Xa inhibitors: pharmacological characteristics and clinical evidence]Toshitaka Yajima, Mitsuo Higashimori, Chie Takata, et al.
Pharmaceutical Statistics|August 27, 2019
Optimal designs for regional bridging studies using the Bayesian power prior methodMario Nagase, Shinya Ueda, Mitsuo Higashimori, et al.
Molecular Pharmaceutics|December 20, 2022
Prediction of the Contribution Ratio of a Target Metabolic Enzyme to Clearance from Chemical Structure InformationReiko Watanabe, Toshio Kawata, Shinya Ueda, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|September 4, 2019
Assessing pharmacokinetic differences in Caucasian and East Asian (Japanese, Chinese and Korean) populations driven by CYP2C19 polymorphism using physiologically-based pharmacokinetic modellingLi Zhou, Pradeep Sharma, Karen Rowland Yeo, et al.
Cancer Chemotherapy and Pharmacology|February 15, 2019
Gefitinib exposure and occurrence of interstitial lung disease in Japanese patients with non-small-cell lung cancerToshio Kawata, Mitsuo Higashimori, Yohji Itoh, et al.
Clinical Pharmacology and Therapeutics|February 26, 2019
Oncology Therapy Drugs in China, Japan, and the United States: Pharmacokinetic Characteristics, Dose Regimens, and Development StrategiesLi Zhou, Mitsuo Higashimori, Kai Shen, et al.
Clinical Pharmacology in Drug Development|November 27, 2021
Surveys/Research Exploring Japanese Phase I Studies in Global Drug Development: Are They Necessary Prior to Joining Global Clinical Trials?Masaru Hirano, Masanori Yamada, Toshiaki Tanaka, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Journal of Pharmacokinetics and Pharmacodynamics|December 3, 2003
Mean hepatic recovery ratio in capacity-limited first-pass effect by three-point sampling methodMitsuo Higashimori, Kiyoshi Yamaoka
Journal of Pharmaceutical Sciences|April 3, 2020
Physiologically Based Pharmacokinetic Modelling of Glycopyrronium in Patients With Renal ImpairmentMitsuo Higashimori, Kensuke Ishikawa, Michael Gillen, et al.
International Journal of Clinical Pharmacology and Therapeutics|October 29, 2019
Physiologically based pharmacokinetic modeling to predict exposures in healthy Japanese subjects with different CYP2C19 phenotypes: Esomeprazole case study
Mitsuo Higashimori, Hitoshi Shimada, Katsuomi Ichikawa, et al.
Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica|January 3, 2023
[Andexanet alfa (ONDEXXYA<sup>®</sup> for Intravenous Injection 200 mg), a reversal agent for direct factor Xa inhibitors: pharmacological characteristics and clinical evidence]Toshitaka Yajima, Mitsuo Higashimori, Chie Takata, et al.
Pharmaceutical Statistics|August 27, 2019
Optimal designs for regional bridging studies using the Bayesian power prior methodMario Nagase, Shinya Ueda, Mitsuo Higashimori, et al.
Molecular Pharmaceutics|December 20, 2022
Prediction of the Contribution Ratio of a Target Metabolic Enzyme to Clearance from Chemical Structure InformationReiko Watanabe, Toshio Kawata, Shinya Ueda, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|September 4, 2019
Assessing pharmacokinetic differences in Caucasian and East Asian (Japanese, Chinese and Korean) populations driven by CYP2C19 polymorphism using physiologically-based pharmacokinetic modellingLi Zhou, Pradeep Sharma, Karen Rowland Yeo, et al.
Cancer Chemotherapy and Pharmacology|February 15, 2019
Gefitinib exposure and occurrence of interstitial lung disease in Japanese patients with non-small-cell lung cancerToshio Kawata, Mitsuo Higashimori, Yohji Itoh, et al.
Clinical Pharmacology and Therapeutics|February 26, 2019
Oncology Therapy Drugs in China, Japan, and the United States: Pharmacokinetic Characteristics, Dose Regimens, and Development StrategiesLi Zhou, Mitsuo Higashimori, Kai Shen, et al.
Clinical Pharmacology in Drug Development|November 27, 2021
Surveys/Research Exploring Japanese Phase I Studies in Global Drug Development: Are They Necessary Prior to Joining Global Clinical Trials?Masaru Hirano, Masanori Yamada, Toshiaki Tanaka, et al.
Pageof 2